Republic Technologies Announces 2025 AGSM Results

Republic Technologies Announces 2025 AGSM Results

Republic Technologies Inc. (CSE: DOCT,OTC:DOCKF) (FSE: 7FM0) (the "Company" or "Republic") is pleased to announce that all matters put forth at the Company's Annual General and Special Meeting of Shareholders (the "Meeting") held on August 19, 2025 were approved by its shareholders.

The Company's shareholders voted to fix the number of directors of the Company at four and elected the following four nominees to the board of directors: Daniel Liu, Hongming Luo, Tianrui Zhang and Litong Cao. Each of the nominees will hold office until the next annual meeting of shareholders, unless he or she sooner ceases to hold office.

The shareholders appointed Charlton & Company, CPA as the auditor of the Company.

The shareholders also passed (i) an ordinary resolution approving the adoption of a new 20% rolling long-term incentive plan; and (ii) a special resolution approving the deletion and replacement of the Company's Articles. A copy of the Company's Articles is available under the Company's profile on SEDAR+ (www.sedarplus.ca).

Additional information regarding each of the items approved at the Meeting is set out in the Company's Information Circular dated July 8, 2025, that is available on SEDAR+ (www.sedarplus.ca) under the Company's profile.

About Republic Technologies Inc.

Republic Technologies is a publicly traded technology company integrating Ethereum infrastructure into the global economy. Backed by an ETH-denominated treasury, we operate proprietary validator and attestation networks to safeguard data integrity for universal applications.

On behalf of the Board of Directors,
Daniel Liu, Chief Executive Officer
Email: daniel@republictech.io
https://republictech.io/

Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the accuracy or adequacy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263290

News Provided by Newsfile via QuoteMedia

DOCT:CNX
The Conversation (0)
beyond medical

Beyond Medical Technologies

Keeping Canadians Healthy and Safe

Keeping Canadians Healthy and Safe Keep Reading...
Scientists working in a modern medical research laboratory.

Pathways to Commercialising Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at... Keep Reading...
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the... Keep Reading...
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries CommenceDownload the PDF here. Keep Reading...
Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities. The groundbreaking developments in antifungal treatments specifically targeting women's health issues... Keep Reading...
Zero Candida Technologies (TSXV:ZCT)

Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company... Keep Reading...

Interactive Chart

Latest Press Releases

Related News